By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

作者: M R Law , N J Wald , S G Thompson

DOI: 10.1136/BMJ.308.6925.367

关键词:

摘要: Objective : To estimate by how much and quickly a given reduction in serum cholesterol concentration will reduce the risk of ischaemic heart disease. Design Data on incidence disease were analysed from 10 prospective (cohort) studies, three international studies different communities, 28 randomised controlled trials (with mortality data according to allocated treatment ensure avoidance bias). Main outcome measure - Decrease or for 0.6 mmol/l (about 10%) decrease concentration. Results For men results cohort showed that was associated with 54% at age 40 years, 39% 50, 27% 60, 20% 70, 19% 80. The combined (for ages 55-64 years) 38% (95% confidence interval 33% 42%), somewhat greater than study 27%. reductions 7% (0 14%) first two 22% (15% 28%) 2.1-5 25% 35%) after five last being lose long term studies. women are limited but indicate similar effect. Conclusions comparisons, clinical remarkably consistent. based half million 18 000 events, (10%), which can be achieved moderate dietary change,lowers 50% 40, falling 70. trials, 45 4000 events show full effect is years.

参考文章(68)
J. Marmorston, F. J. Moore, C. E. Hopkins, O. T. Kuzma, J. Weiner, Clinical Studies of Long-Term Estrogen Therapy in Men with Myocardial Infarction Experimental Biology and Medicine. ,vol. 110, pp. 400- 408 ,(1962) , 10.3181/00379727-110-27531
Greg Brown, John J. Albers, Lloyd D. Fisher, Susan M. Schaefer, Jiin-Tarng Lin, Cheryl Kaplan, Xue-Qiao Zhao, Brad D. Bisson, Virginia F. Fitzpatrick, Harold T. Dodge, Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B The New England Journal of Medicine. ,vol. 323, pp. 1289- 1298 ,(1990) , 10.1056/NEJM199011083231901
Henry Buchwald, Richard L. Varco, John P. Matts, John M. Long, Laurie L. Fitch, Gilbert S. Campbell, Malcolm B. Pearce, Albert E. Yellin, W. Allan Edmiston, Robert D. Smink, Henry S. Sawin, Christian T. Campos, Betty J. Hansen, Naip Tuna, James N. Karnegis, Miguel E. Sanmarco, Kurt Amplatz, Wilfredo R. Castaneda-Zuniga, David W. Hunter, Joseph K. Bissett, Frederic J. Weber, James W. Stevenson, Arthur S. Leon, Thomas C. Chalmers, Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) The New England Journal of Medicine. ,vol. 323, pp. 946- 955 ,(1990) , 10.1056/NEJM199010043231404
M. Heikki Frick, Olli Elo, Kauko Haapa, Olli P. Heinonen, Pertti Heinsalmi, Pekka Helo, Jussi K. Huttunen, Pertti Kaitaniemi, Pekka Koskinen, Vesa Manninen, Hanna Mäenpää, Marjatta Mälkönen, Matti Mänttäri, Seppo Norola, Amos Pasternack, Jarmo Pikkarainen, Matti Romo, Tom Sjöblom, Esko A. Nikkilä, Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia New England Journal of Medicine. ,vol. 317, pp. 1237- 1245 ,(1987) , 10.1056/NEJM198711123172001
Lars A. Carlson, Stephan Rössner, Coronary Drug Project Research Group. Atherosclerosis. ,vol. 30, pp. 241- ,(1978) , 10.1016/0021-9150(78)90051-5
Begg Tb, Rifkind Bm, Evaluation of clofibrate therapy in peripheral arteriopathy Minerva Medica. ,vol. 62, pp. 3469- 3475 ,(1971)